Exelixis drops tissue factor-targeting ADC after deciding it's no match for Tivdak

cafead

Administrator
Staff member
  • cafead   Aug 07, 2024 at 11:22: AM
via Exelixis is giving up on its tissue factor (TF)-targeting antibody-drug conjugate after concluding the candidate was unlikely to best Pfizer and Genmab’s Tivdak.

article source
 

<